BIIB
$292.23
Biogen
($12.92)
(4.23%)
BIIB
Earnings Whisper ®
N/A
4th Quarter December 2022
Consensus:  $3.41
Revenue:  $2.44 Bil
Tuesday
Jan 24
7:15 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS
Tuesday, October 25, 2022

What do you expect when BIIB reports earnings?
Beat
Meet
Miss

Where is BIIB's stock price going from here?
Up
Flat
Down
Stock chart of BIIB
Analysts
Summary of analysts' recommendations for BIIB
Score
Grade
Pivots
Resistance
$312.38
$309.95
$307.55

$305.13

Support
$302.72
$300.30
$297.90
Tweet
Growth
Description
Biogen is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. The company owns industry leading brands for the treatment of multiple sclerosis, next-generation treatments for hemophilia, and a deep clinical pipeline ranging from Alzheimer's disease, lupus nephritis to neuropathic pain.
Peers
Neurocrine BiosciencesGilead SciencesSeagen Inc.AmgenBioCryst PharmaceuticalsBluebird BioSangamo TherapeuticsQiagen N.V.RepligenStem